Key result
Addition of sirolimus to aggressive immunosuppressive therapy resulted in the patient remaining disease-free from recurrent giant cell myocarditis post-heart transplantation.
Why the study?
Does sirolimus prevent recurrence of giant cell myocarditis in a heart transplant recipient?
Case Report (n=1)
Does sirolimus prevent recurrence of giant cell myocarditis in a heart transplant recipient?
Sirolimus may be an effective adjunctive therapy for preventing recurrence of giant cell myocarditis after heart transplantation.
Answers are grounded in this paper and cite their sources.
May inform individualized therapy for recurrent post-transplant GCM with Crohn disease; hypothesis-generating and should not yet change practice.
CLINICAL FEATURES: Giant cell myocarditis (GCM) is a rare and a rapidly progressive disorder with fatal outcomes such that patients often require heart transplantation. We present a case of recurrent GCM in a transplanted patient with a history of Crohn disease requiring a novel therapeutic approach. THERAPEUTIC CHALLENGE: After the orthotopic heart transplantation, GCM recurred on aggressive immunosuppression over the months, which included corticosteroids, basiliximab, tacrolimus, antithymocyte globulin, and rituximab. Although combination immunosuppressive therapy containing cyclosporine and 2-4 additional drugs including corticosteroids, azathioprine, mycophenolate mofetil, muromonab, gammaglobulin, or methotrexate have shown to prolong the transplant-free survival by keeping the disease under control, its role in preventing and treating recurrence posttransplantation is unclear. SOLUTION: We added sirolimus, a macrolide antibiotic, with properties of T- and B-lymphocyte proliferation inhibition on the above immunosuppressive treatment postrecurrence of GCM. After sirolimus initiation and continuation, the patient has remained disease free.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2018) conducted a case report in Recurrent Giant Cell Myocarditis (n=1). Sirolimus was evaluated on Disease recurrence. Addition of sirolimus to aggressive immunosuppressive therapy resulted in the patient remaining disease-free from recurrent giant cell myocarditis post-heart transplantation.
Synapse has enriched 10 related papers. Consider them for comparative context: